CTVD Highlights - 2017
The Collaboration for TB Vaccine Discovery (CTVD) 3rd Annual meeting was held June 22 and 23, 2017 at the Bill & Melinda Gates Foundation Seattle campus. Remarkable novel TB vaccine-related data were presented at this collaborative and productive meeting, with 145 participants from academia, independent research institutes, industry, funding organizations and the Gates Foundation. During the first day, experts discussed topics such as advances in the TB vaccine discovery and testing space, lessons learned from basic immunology efforts relevant for TB vaccines, and controlled human infection models. Gates Foundation CEO, Sue Desmond Hellmann, discussed precision medicine and whether it can be applied to TB vaccines. We heard exciting presentations from some of our leading junior investigators as well as CMV and RNA vaccine updates. For the second day, the six different CTVD research communities shared their outputs as well as their future areas of exploration and collaboration. CTVD has grown over the last 3 years and now includes 51 member institutions from the US, Europe, Africa, Latin America, and Asia.